{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:31:10Z","timestamp":1777599070016,"version":"3.51.4"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T00:00:00Z","timestamp":1424822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>\n                      To study the effects of saxagliptin, a dipeptidyl peptidase\u20104 inhibitor, on glycaemic stability and \u03b2\u2010cell function in the\n                      <jats:styled-content style=\"fixed-case\">SAVOR\u2010TIMI<\/jats:styled-content>\n                      53 trial.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We randomized 16\u2009492 patients with type 2 diabetes (\n                      <jats:styled-content style=\"fixed-case\">T2D<\/jats:styled-content>\n                      ) to saxagliptin or placebo, added to current antidiabetic medications, and followed them for a median of 2.1\u2009years. Glycaemic instability was defined by: (i) a glycated haemoglobin (\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      ) increase of \u22650.5% post\u2010randomization; (ii) the initiation of new antidiabetic medications for \u22653\u2009months; or (iii) an increase in dose of oral antidiabetic medication or \u226525% increase in insulin dose for \u22653\u2009months. \u03b2\u2010cell function was assessed according to fasting homeostatic model 2 assessment of \u03b2\u2010cell function (\n                      <jats:styled-content style=\"fixed-case\">HOMA<\/jats:styled-content>\n                      \u20102\u03b2) values at baseline and at year 2 in patients not treated with insulin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with placebo, participants treated with saxagliptin had a reduction in the development of glycaemic instability (hazard ratio 0.71; 95% confidence interval 0.68\u20130.74; p\u2009&lt;\u20090.0001). In participants treated with saxagliptin compared with placebo, the occurrence of an\n                      <jats:styled-content style=\"fixed-case\">HbA1c<\/jats:styled-content>\n                      increase of \u22650.5% was reduced by 35.2%; initiation of insulin was decreased by 31.7% and the increases in doses of an oral antidiabetic drug or insulin were reduced by 19.5 and 23.5%, respectively (all p\u2009&lt;\u20090.0001). At 2\u2009years,\n                      <jats:styled-content style=\"fixed-case\">HOMA<\/jats:styled-content>\n                      \u20102\u03b2 values decreased by 4.9% in participants treated with placebo, compared with an increase of 1.1% in those treated with saxagliptin (p\u2009&lt;\u20090.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Saxagliptin improved glycaemia and prevented the reduction in\n                      <jats:styled-content style=\"fixed-case\">HOMA<\/jats:styled-content>\n                      \u20102\u03b2 values. Saxagliptin may reduce the usual decline in \u03b2\u2010cell function in\n                      <jats:styled-content style=\"fixed-case\">T2D<\/jats:styled-content>\n                      , thereby slowing diabetes progression.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.12445","type":"journal-article","created":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T04:38:09Z","timestamp":1423111089000},"page":"487-494","source":"Crossref","is-referenced-by-count":31,"title":["Impact of treatment with saxagliptin on glycaemic stability and\u00a0\u03b2\u2010cell function in the\n                    <scp>SAVOR\u2010TIMI<\/scp>\n                    53 study"],"prefix":"10.1111","volume":"17","author":[{"given":"G.","family":"Leibowitz","sequence":"first","affiliation":[{"name":"The Diabetes Unit Hadassah University Hospital  Jerusalem Israel"},{"name":"The Endocrine Service Hadassah University Hospital  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Cahn","sequence":"additional","affiliation":[{"name":"The Diabetes Unit Hadassah University Hospital  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"TIMI Study Group Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hirshberg","sequence":"additional","affiliation":[{"name":"AstraZeneca Research and Development  Wilmington DE USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Mosenzon","sequence":"additional","affiliation":[{"name":"The Diabetes Unit Hadassah University Hospital  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Wei","sequence":"additional","affiliation":[{"name":"AstraZeneca Research and Development  Wilmington DE USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Jermendy","sequence":"additional","affiliation":[{"name":"Bajcsy\u2010Zsilinszky Hospital, Medical Department  Budapest Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. H.\u2010H.","family":"Sheu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism Taichung Veterans General Hospital  Taichung Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. L.","family":"Sendon","sequence":"additional","affiliation":[{"name":"Hospital Universitario La Paz, Instituto de investigaci\u00f3n IdiPaz  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Im","sequence":"additional","affiliation":[{"name":"TIMI Study Group Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Braunwald","sequence":"additional","affiliation":[{"name":"TIMI Study Group Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. M.","family":"Scirica","sequence":"additional","affiliation":[{"name":"TIMI Study Group Brigham and Women's Hospital, Harvard Medical School  Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Raz","sequence":"additional","affiliation":[{"name":"The Diabetes Unit Hadassah University Hospital  Jerusalem Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,2,25]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<290::AID-DIA570>3.0.CO;2-M"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg040"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.11.1249"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)03062-6"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2009.11.006"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.5.995"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-1995"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2002.00743.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2009.03.011"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.04.008"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-013-2927-8"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2013.09.010"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.08.006"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2413"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1487"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0650"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1105911"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.10.001"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12312"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.922"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ12-0357"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2000.00708.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/1403494812459814"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61190-8"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12445","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T05:36:19Z","timestamp":1761888979000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,25]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1111\/dom.12445"],"URL":"https:\/\/doi.org\/10.1111\/dom.12445","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,25]]}}}